Häufige Suchbegriffe
Search results
6 results found-
R&D Investor Briefing 2017
Autoimmune conditions Improved target binding Recombinant Fc Multimer - CSL730 CSL / Momenta Collaboration . First-in-class recombinant Fc multimer targeting Fcγ receptors .
https://www.cslbehring.ch/-/media/shared/documents/7/rd-investor-briefing-2017.pdf -
PowerPoint Presentation
CSL842 Phase III Randomised, Placebo-controlled Withdrawal | Driven by Our Promise (tm) 82 | Driven by Our Promise (tm) 82 Vitaeris and CSL Strategic Collaboration in AMR | Driven
https://www.cslbehring.ch/-/media/cslb-switzerland/documents/rd-investor-briefing-2018.pdf